Autoimmune Complications Associated with Lemtrada Solved Using Anti-CD20 Therapies, Case Studies Suggest
One of the concerns about the disease-modifying therapy (DMT) Lemtrada (alemtuzumab) is that it may raise the patient’s risk of developing a secondary autoimmune disease within seven years post-treatment. This small study suggests that the abnormal proliferation of B-cells in some patients caused by Lemtrada treatment might be resolved with the DMTs Ocrevus (ocrelizumab) or rituximab.
Anti-CD20 therapies, including rituximab or Ocrevus (ocrelizumab), are a potential treatment for Lemtrada-associated autoimmune complications in patients who fail to respond to other conventional immunotherapies, according to a case report about two women in Australia.
Click here to read the full story.
This news isn’t specific to multiple sclerosis, because currently in the U.S., the